Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21231890 | 1.00 | GRIN1 (0.50) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL3993491 | 0.83 | GRIN1 (0.61) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL3990887 | 0.81 | GRIN1 (0.55) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL21231892 | 0.81 | SIGMAR1 (0.34) | — | |
| SCHEMBL31757292 | 0.79 | TSHR (0.54) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL21166718 | 0.79 | TSHR (0.54) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL29209237 | 0.79 | GRIN1 (0.67) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL19688701 | 0.79 | GRIN1 (0.67) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL4408028 | 0.78 | GRIN1 (0.56) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL19386242 | 0.75 | GRIN1 (0.68) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533444-A1 | PHARMACEUTICAL APPLICATIONS FOR (S)-NORKETAMINE AND SALTS THEREOF | National University Corporation Chiba University (JP) | 2019-09-04 | — | — | EP | claimed |
| US-20190240184-A1 | PHARMACEUTICAL APPLICATIONS FOR (S)-NORKETAMINE AND SALTS THEREOF | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2019-08-08 | — | — | US | claimed |
| EP-3533444-A1 | PHARMACEUTICAL APPLICATIONS FOR (S)-NORKETAMINE AND SALTS THEREOF | National University Corporation Chiba University (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-20190240184-A1 | PHARMACEUTICAL APPLICATIONS FOR (S)-NORKETAMINE AND SALTS THEREOF | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240184-A1 | PHARMACEUTICAL APPLICATIONS FOR (S)-NORKETAMINE AND SALTS THEREOF | SYMPK, KHK, BCKDK | GRIN1 281/4885GRIN2A 198/4885SLC6A4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.